Current and Future Use of MET Inhibitors in NSCLC
April 26th 2021Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.
Read More
MET Inhibitors in NSCLC: Mechanisms of Resistance
April 26th 2021The rationale for using MET inhibitors as first-line therapy for patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations and considerations for sequencing later lines of therapy based on what is known to date about mechanisms of resistance to MET inhibitors.
Read More
MET Inhibitors in NSCLC: Toxicity Management
April 19th 2021Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.
Read More
WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
February 26th 2021Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).
Read More